Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Assets (2016 - 2025)

Veracyte's Assets history spans 14 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Assets rose 8.15% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 8.15%, while the annual FY2025 figure was $1.4 billion, 8.15% up from the prior year.
  • Assets for Q4 2025 was $1.4 billion at Veracyte, up from $1.4 billion in the prior quarter.
  • Across five years, Assets topped out at $1.4 billion in Q4 2025 and bottomed at $1.0 billion in Q1 2021.
  • The 5-year median for Assets is $1.2 billion (2021), against an average of $1.2 billion.
  • The largest annual shift saw Assets surged 300.19% in 2021 before it dropped 5.09% in 2022.
  • A 5-year view of Assets shows it stood at $1.2 billion in 2021, then dropped by 2.64% to $1.2 billion in 2022, then dropped by 3.59% to $1.1 billion in 2023, then increased by 16.6% to $1.3 billion in 2024, then grew by 8.15% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Assets are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.3 billion (Q2 2025).